Clinical Trials Logo

Vaginal Microbiome clinical trials

View clinical trials related to Vaginal Microbiome.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06356012 Not yet recruiting - Biomarkers Clinical Trials

Clinical Outcome and Biomarkers for Predicting Immunological Response in Patients Treated With Imiquimod

Start date: April 2, 2024
Phase: Phase 4
Study type: Interventional

The goal of this clinical trial is to identify the immunophenotypic profile of the local immune response, the cervicovaginal microenvironment and the microbiological profile of women with CIN 3 treated with imiquimod. Participants will be divided in 3 groups: CIN 3 who will use 16 doses of imiquimod in the uterine cervix, applied twice a week and will be treated with LEEP procedure; 2) patients with CIN 3 who will undergo standard treatment with LEEP procedure; 3) patients with negative cytology and HPV (human papillomavirus) test. Blood and cervicovaginal lavage collections will be performed at different times, for comparisons between cellular response profiles to imiquimod during treatment and baseline levels in healthy patients.

NCT ID: NCT05000112 Not yet recruiting - Vaginal Microbiome Clinical Trials

Vaginal Microbiome-host Interaction in Mesh Exposure After TVM Surgery

Start date: September 2021
Phase:
Study type: Observational

Transvaginal pelvic mesh implantation(TVM) is a foreign body implantation operation with intraoperative colonization of vaginal bacteria. However, the vaginal microbiome-host interaction and its influence in the mechanism of mesh exposure after TVM remains unclear. This study will enroll post-TVM patients with and without mesh exposure and use their vaginal swabs to perform TRACE-seq and cytokine analysis. The microbiome-host interactions related with mesh exposure and the changes in protein expression will be analyzed.